On September 18, Fidelity's Wise Origin Bitcoin Fund (FBTC) attracted $310.72 million in net inflows, making up about 72% of all US spot Bitcoin ETF purchases that day. Total inflows across all US spot Bitcoin ETFs reached $433 million, with Fidelity and BlackRock's IBIT capturing 97% of the capital. Since its launch in January 2024, FBTC has accumulated over $10 billion in net inflows, contributing to a total of $102.53 billion in assets under management for US spot Bitcoin ETFs, which now represent over 6% of Bitcoin's market capitalization. This strong demand for Bitcoin ETFs supports Bitcoin's price by tightening supply and highlights the growing importance of ETFs in the market structure.
Fidelity's Wise Origin Bitcoin Fund saw $310.72 million in net inflows on a single day, dominating US spot Bitcoin ETF purchases. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 19, 2026 14:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 43 rose and 6 fell. Notable movers include AVAX at Rp150.638 (+7.81%), XRP at Rp25.211 (+7.40%), and UNI at Rp162.945 (+7.29%).
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
